Cost-utility analysis of osimertinib and dacomitinib in the first-line treatment of advanced non-small cell lung cancer with EGFR mutation
Expert Review of Pharmacoeconomics & Outcomes Research · 2025
DOI: 10.1080/14737167.2025.2518135 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2025. Verfasst von Lili Su und 4 weiteren Autor:innen. Beteiligte Einrichtung: Tianjin Cancer Hospital Airport Hospital, National Clinical Research Center for Cancer, Tianjin, China. Hauptthemen laut MEDLINE: Aniline Compounds, Carcinoma, Non-Small-Cell Lung, Quinazolinones, Acrylamides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Wu Jieping Medical Foundation.
Abstract (Originalsprache)
OBJECTIVE: To evaluate the cost-effectiveness of osimertinib compared to dacomitinib for advanced non-small cell lung cancer with EGFR mutation from the perspective of China's health system. METHODS: Based on the FLAURA clinical trial and network meta-analysis, a partitioned survival model was constructed with a model simulation timeframe of 10 years and a 3-week cycle. Cost and quality-adjusted life years (QALYs) were used as model output indicators, and the incremental cost-effectiveness ratio was calculated to determine the economic feasibility of osimertinib compared to dacomitinib through cost-utility analysis. Sensitivity analysis was applied to test the robustness of the model. RESULTS: The basic analysis results indicate that the osimertinib group incurred an additional cost of 138,487 Chinese Yuan (CNY) compared to the dacomitinib group, but gained an additional 0.32 QALYs. The incremental cost-effectiveness ratio is 436,203 CNY, which is higher than three times China's per capita GDP. CONCLUSION: Under the threshold of three times China's per capita GDP, osimertinib appears not to be cost-effective compared to dacomitinib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tianjin Cancer Hospital Airport Hospital, National Clinical Research Center for Cancer, Tianjin, China.
- Department of Pharmacy, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
ORCID-Profile: Lili Su, Mengrong Li
Förderung
- Wu Jieping Medical Foundation
Zitieren
APA
Su, L., Zhang, X., Li, M., Li, Y., & Wang, D. (2025). Cost-utility analysis of osimertinib and dacomitinib in the first-line treatment of advanced non-small cell lung cancer with EGFR mutation. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2025.2518135
Vancouver
Su L, Zhang X, Li M, Li Y, Wang D. Cost-utility analysis of osimertinib and dacomitinib in the first-line treatment of advanced non-small cell lung cancer with EGFR mutation. Expert Review of Pharmacoeconomics & Outcomes Research. 2025. doi:10.1080/14737167.2025.2518135
BibTeX
@article{Su2025,
author = {Su, Lili and Zhang, Xiangyu and Li, Mengrong and Li, Ying and Wang, Dong},
title = {Cost-utility analysis of osimertinib and dacomitinib in the first-line treatment of advanced non-small cell lung cancer with EGFR mutation},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2025},
doi = {10.1080/14737167.2025.2518135}
}
EUVIMED